Phase I/II Study of MLN8237 in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Mar 2017
At a glance
- Drugs Alisertib (Primary) ; Irinotecan; Temozolomide
- Indications Neuroblastoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 21 Mar 2017 Planned End Date changed from 1 Jun 2016 to 1 Dec 2017.
- 21 Mar 2017 Planned primary completion date changed from 1 May 2016 to 1 Jun 2017.